# MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients

> **NCT02560220** · PHASE1 · COMPLETED · sponsor: **Heidelberg University** · enrollment: 14 (actual)

## Conditions studied

- Kidney Failure, Chronic

## Interventions

- **BIOLOGICAL:** Mitomycin C-induced peripheral blood mononuclear cells (MICs)

## Key facts

- **NCT ID:** NCT02560220
- **Lead sponsor:** Heidelberg University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-05
- **Primary completion:** 2017-04-18
- **Final completion:** 2017-04-18
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2018-07-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02560220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02560220, "MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02560220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*